Physician profile
Ali Mustafa
NPI 1891226486
$2,219.97
in general payments reported to CMS, 2019-2025
25 companies · $1,699 in 2025
The $1,699 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $521 · 2025: $1,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,113 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,112.67 |
| Education | $107.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $608.43 | 2024-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $271.91 | 2024-2025 | Airsupra, Fasenra, Breztri |
| Ani Pharmaceuticals, INC. | $194.66 | 2024-2025 | Purified Cortrophin Gel |
| Edwards Lifesciences Corporation | $142.87 | 2025 | Sapien 3 Ultra Resilia |
| Genzyme Corporation | $106.40 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.28 | 2024-2025 | Ofev, Jascayd |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Philips North America LLC | $96.01 | 2025 | Vest Therapy Und |
| Takeda Pharmaceuticals U.S.A., INC. | $94.59 | 2025 | Aralast |
| Regeneron Healthcare Solutions, INC. | $90.84 | 2024-2025 | Dupixent |
| Baxter Healthcare | $62.52 | 2025 | |
| Harmony Biosciences LLC | $52.94 | 2024-2025 | |
| Genentech USA, INC. | $40.66 | 2025 | Xolair |
| Insmed, INC. | $37.43 | 2025 | Arikayce, Brinsupri |
| Avadel Cns Pharmaceuticals, LLC | $35.34 | 2025 | Lumryz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 3b Medical, INC. | $31.08 | 2025 | Luna |
| Jazz Pharmaceuticals INC. | $18.98 | 2024 | |
| Amgen INC. | $18.75 | 2025 | Tezspire |
| Electromed, INC. | $18.26 | 2025 | Smartvest |
| Abiomed | $18.24 | 2024 | Impella |
| Actelion Pharmaceuticals US, INC. | $16.97 | 2024 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $15.62 | 2025 | Winrevair |
| Lilly USA, LLC | $15.24 | 2025 | Zepbound |
| United Therapeutics Corporation | $15.01 | 2025 | Tyvaso |
| Viatris Specialty LLC | $14.99 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Mustafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.